Recent 8-K filings for ONCY

• July 13, 2026, 9:03 AM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Oncolytics: FDA Type D meeting in Aug; half of REO 033 sites activated, >20 patients pre-identified

  Company to hold Type D meeting with FDA in first half of August 2026 to discuss registrational design for REO 033 Part B.

• July 8, 2026, 4:23 PM ET other material materiality 0.40 neutral item 4.01item 9.01

  Oncolytics Biotech disengages EY, engages Baker Tilly as auditor after restructuring

  Audit committee voted to disengage EY and engage Baker Tilly for fiscal 2026, subject to client acceptance.

• June 16, 2026, 9:05 AM ET other material materiality 0.65 positive item 8.01item 9.01

  Oncolytics secures new U.S. patent for pelareorep manufacturing through 2044; method-of-use app to 2046

  USPTO issued patent covering pelareorep manufacturing process, expected protection into 2044.

• June 2, 2026, 9:02 AM ET leadership materiality 0.50 neutral item 5.02item 8.01item 9.01 ◈ executive_change ×2

  Oncolytics appoints Steve Glover to board, promotes John McAdory to COO

  Steve Glover appointed to board effective June 1, 2026; he chaired Ambrx during its $2B J&J acquisition.

• June 1, 2026, 9:06 AM ET other material materiality 0.45 positive item 8.01item 9.01

  Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned

  Initial data in solid tumor model shows greater anti-tumor activity with pelareorep+RAS inhibitor vs either alone.

• May 22, 2026, 9:03 AM ET other material materiality 0.55 positive item 8.01item 9.01

  Oncolytics posts translational data from GOBLET/AWARE-1 at ASCO 2026 supporting pelareorep immune activation

  Data from GOBLET (advanced pancreatic cancer) and AWARE-1 (early-stage breast cancer) to be presented at ASCO 2026 May 29-June 2.

• May 4, 2026, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Oncolytics reports 19.5-month median DOR in 2L RAS-mutant MSS mCRC; triples ORR vs SOC

  Pelareorep-based combo shows median duration of response 19.5 months in 2L KRAS-mutant MSS mCRC, vs historical 4–6 months.

• April 27, 2026, 7:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  Oncolytics secures FDA alignment on pivotal anal cancer study for pelareorep

  FDA agreed on a randomized controlled pivotal trial design for pelareorep in post-first-line metastatic SCAC, targeting accelerated and full approval.

• April 6, 2026, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Oncolytics Biotech enters ATM agreement for up to $75M common stock offering

  Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.

• April 6, 2026, 7:59 PM ET regulatory materiality 0.55 positive item 8.01item 9.01

  Oncolytics schedules Type C FDA meeting for pelareorep single-arm study in anal cancer

  FDA meeting set for April 16, 2026 to discuss single-arm pivotal study of pelareorep + checkpoint inhibitor in SCAC.

• April 1, 2026, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 3.03item 5.03item 5.02item 8.01item 9.01 ◈ Equity Issuances◈ Governance Changes

  Oncolytics Biotech completes redomestication to Nevada; adopts new equity plan and governance documents

  Redomestication from Canada to Nevada completed; common stock continues trading on Nasdaq under ONCY.

• March 20, 2026, 7:59 PM ET other material materiality 0.35 neutral item 3.03item 5.03item 9.01 ◈ Governance Changes

  Oncolytics completes continuance to BC; expects Nevada domestication by March 31

  First step completed March 17: continuance from Alberta to British Columbia under BCBCA.

• March 19, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer

  GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.

• March 2, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Oncolytics launches Phase 2 REO 033 trial in 2L RAS-mutant MSS mCRC; preliminary data expected by end of 2026

  Randomized Phase 2 study (REO 033) of pelareorep + bevacizumab + FOLFIRI vs bevacizumab + FOLFIRI in 30 patients per arm.

• February 24, 2026, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Oncolytics prioritizes SCAC and CRC registration studies; GOBLET enrollment closed

  Concluded enrollment in GOBLET gastrointestinal study; now focusing on registrational studies in squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC).

• February 4, 2026, 6:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  Oncolytics gets FDA Fast Track for pelareorep in 2L KRAS-mutant MSS mCRC; interim data expected YE 2026

  FDA Fast Track Designation for pelareorep + bevacizumab + FOLFIRI in second-line KRAS-mutant MSS metastatic colorectal cancer.

• January 15, 2026, 6:59 PM ET leadership materiality 0.65 positive item 8.01item 9.01

  Oncolytics appoints EVP John McAdory and VP Biostatistics Yujun Wu, grants inducement awards

  John McAdory named EVP Strategy & Operations; previously VP Clinical Ops at CG Oncology (Nasdaq: CGON).

• January 15, 2026, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Oncolytics shareholders OK continuance to BC and domestication to Nevada

  Continuance from Alberta to British Columbia approved: 85.21% in favor.

• January 12, 2026, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Oncolytics: GOBLET Cohort 4 third-line anal cancer ORR 29%; median DOR ~17 months; files new patent application

  GOBLET Cohort 4: 4/14 evaluable third-line anal cancer patients responded (ORR 29%), 2 CRs, 2 PRs; median DOR ~17 months vs historical ~10%.

Executive changes

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

13 positive 0 negative 6 neutral

source · ONCY on sec.gov